First-in-Human, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of Single Ascending Doses in Healthy Volunteers and Multiple Ascending Doses in Subjects With Type 2 Diabetes to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PATAS
Latest Information Update: 25 Feb 2026
At a glance
- Drugs PATAS (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors AdipoPharma
Most Recent Events
- 27 Jan 2026 Planned initiation date changed from 5 Jan 2026 to 27 Jan 2026.
- 27 Jan 2026 Status changed from not yet recruiting to recruiting.
- 19 Jan 2026 Planned initiation date changed from 10 Dec 2025 to 5 Jan 2026.